Last reviewed · How we verify
gabapentine
At a glance
| Generic name | gabapentine |
|---|---|
| Also known as | Anticonvulsant |
| Sponsor | Dominik Irnich |
| Target | Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Partial Epilepsy Treatment Adjunct
- Postherpetic neuralgia
- Restless legs
Common side effects
Key clinical trials
- Procedural Framing and Epidural Steroid Injection Outcomes (NA)
- Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (PHASE2, PHASE3)
- Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients (NA)
- Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study (PHASE3)
- High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer (PHASE3)
- Effect of Gabapentin on Kidney Function Following Laparoscopic Sleeve Gastrectomy(LSG) (PHASE4)
- Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women (PHASE3)
- Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gabapentine CI brief — competitive landscape report
- gabapentine updates RSS · CI watch RSS
- Dominik Irnich portfolio CI